A phase 2/3 trial of BMN 333 in Achondroplasia patients.
Latest Information Update: 08 Oct 2025
At a glance
- Drugs BMN 333 (Primary)
- Indications Achondroplasia
- Focus Registrational; Therapeutic Use
Most Recent Events
- 08 Oct 2025 New trial record
- 04 Aug 2025 Based on results from Phase 1 healthy volunteers study, BioMarin is advancing plans to initiate the registration-enabling Phase 2/3 study in the first half of 2026.